Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Lung Neoplasms 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1Abdomen, Acute 1

Interventions

Cisplatin 33Radiotherapy 23Cetuximab 18Paclitaxel 14Docetaxel 14pembrolizumab 13Carboplatin 12Fluorouracil 10Radiotherapy, Intensity-Modulated 8Nivolumab 8Drug Therapy 7Erlotinib Hydrochloride 6Panitumumab 5dacomitinib 4Radiation 4Methotrexate 4Esophagectomy 4130-nm albumin-bound paclitaxel 4durvalumab 3ON 01910 3Leucovorin 3Gemcitabine 3Chemoradiotherapy 3vandetanib 2palbociclib 2osimertinib 2nedaplatin 2fludarabine 2cabazitaxel 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡